Trophos was a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan

neurodegenerative A neurodegenerative disease is caused by the progressive loss of structure or function of neurons, in the process known as neurodegeneration. Such neuronal damage may ultimately involve cell death. Neurodegenerative diseases include amyotrophic ...

diseases and more prevalent disorders. Trophos was founded in 1999 in

Marseille Marseille ( , , ; also spelled in English as Marseilles; oc, Marselha ) is the prefecture of the French department of Bouches-du-Rhône and capital of the Provence-Alpes-Côte d'Azur region. Situated in the camargue region of southern Fra ...

by three scientists: Christopher Henderson, Olivier Pourquie and Jean-Louis Kraus, and two entrepreneurs: Antoine Beret and Michel Delaage. Trophos' lead compound was

olesoxime Olesoxime (TRO19622) is an experimental drug formerly under development by the now-defunct French company Trophos as a treatment for a range of Neuromuscular disease, neuromuscular disorders. It has a cholesterol-like structure and belongs to the ...

(TRO19622), a mitochondrial targeted compound developed to treat neurodegenerative diseases. In January 2015, Hoffmann-La Roche announced its intention to buy Trophos for upfront and up to in milestone performance payments. The deal was completed shortly afterwards.

References

Further reading